World's 1st fourth-generation BTK inhibitor developed in Guangdong
China's National Medical Products Administration has recently approved Rocbrutinib, a first-in-class fourth-generation BTK inhibitor, for adults with relapsed or refractory mantle cell lymphoma who have received at least two prior systemic therapies, including BTK inhibitors.
2026-06-14 20:23:48